GPC Biotech is a biopharmaceutical company that focuses on the discovery and development of novel anticancer drugs. GPC’s lead product candidate is Satraplatin, an orally administered platinum analog which has successfully completed the phase II clinical trials in hormone-resistant prostate cancer and other tumor types. The company has various anti-cancer programs in research and development that leverage its knowledge in kinase inhibitors.